Insider Buying: Leap Therapeutics, Inc. (LPTX) COO Acquires $6,441,813.21 in Stock
Leap Therapeutics, Inc. (NASDAQ:LPTX) COO Augustine Lawlor acquired 1,057,769 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $6.09 per share, with a total value of $6,441,813.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Leap Therapeutics, Inc. (LPTX) opened at $7.21 on Friday. Leap Therapeutics, Inc. has a fifty-two week low of $4.90 and a fifty-two week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last posted its earnings results on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). analysts expect that Leap Therapeutics, Inc. will post -3.15 EPS for the current year.
Separately, Zacks Investment Research lowered Leap Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned about 0.48% of Leap Therapeutics at the end of the most recent quarter. Institutional investors own 0.81% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Stock Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related stocks with our FREE daily email newsletter.